IPCA Laboratories Share Price
IPCA Laboratories Share Price Today
As of 6 Jul 2026, IPCA Laboratories share price is ₹1,778.90. The stock opened at ₹1,729.00, compared to its previous close of ₹1,719.40. During today's trading session, IPCA Laboratories share price moved in the range of ₹1,719.40 to ₹1,788.30, with an average price of ₹1,753.85 for the day. Looking at its last 52-week, the stock has touched a low of ₹1,251.60 and a high of ₹1,788.30. On the performance front, IPCA Laboratories share price has increased by 26.70% over the last six months and is up 25.66% on a year-on-year basis.
IPCA Laboratories Returns Calculator
IPCA Laboratories Shareholder Returns
IPCA Laboratories Share Price History
| Name | Mkt Cap Cr | P/E | P/B | ROE | D/E | ROCE | Book Value | Div. Yield | Turnover | EPS(TTM) |
|---|---|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries | 4,49,048.00 | 39.02 | 5.37 | 13.74% | 0.61 | 17.33% | 93.24 | 0.85% | 0.56 | 10.90 |
| Divis Laboratories | 1,77,179.00 | 69.00 | 10.57 | 15.32% | 0.00 | 19.56% | 629.49 | 0.45% | 0.58 | 98.19 |
| Torrent Pharmaceuticals | 1,57,804.00 | 66.03 | 17.03 | 26.76% | 1.05 | 18.30% | 16.90 | 0.90% | 0.49 | 64.75 |
| Cipla | 1,17,642.00 | 25.47 | 2.87 | 11.79% | 0.00 | 15.66% | 2.89 | 1.06% | 0.49 | 43.52 |
| Dr. Reddy's Laboratories | 1,12,368.00 | 27.03 | 2.97 | 11.07% | 0.18 | 12.54% | 375.78 | 0.59% | 0.63 | 38.68 |
| Zydus Lifesciences | 1,10,651.00 | 21.60 | 4.08 | 18.59% | 0.31 | 17.35% | 235.25 | 0.09% | 0.39 | 35.38 |
| Lupin | 1,09,676.00 | 20.48 | 4.89 | 23.76% | 0.04 | 24.88% | 659.05 | 0.75% | 0.61 | 129.18 |
| Mankind Pharma | 1,02,729.00 | 53.00 | 6.30 | 11.74% | 0.34 | 13.13% | 397.02 | 0.04% | 0.54 | 49.37 |
| Aurobindo Pharma | 90,608.00 | 25.87 | 2.39 | 9.25% | 0.19 | 11.76% | 391.14 | 0.26% | 0.48 | 41.58 |
| Laurus Labs | 82,398.90 | 60.26 | 10.10 | 18.21% | 0.45 | 16.70% | 10.19 | 0.20% | 0.97 | 13.72 |
IPCA Laboratories Financials
Income Statement · Consolidated
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Revenue | ₹8,939.59 | ₹7,705.04 | ₹6,244.32 | ₹5,829.79 |
| Other Income | ₹92.80 | ₹124.77 | ₹125.62 | ₹66.57 |
| Total Revenue | ₹9,032.39 | ₹7,829.81 | ₹6,369.94 | ₹5,896.36 |
| Total Expenses | ₹7,696.20 | ₹6,879.39 | ₹5,624.65 | ₹4,760.64 |
| Profit Before Tax | ₹1,131.14 | ₹842.67 | ₹745.29 | ₹1,135.72 |
| Tax | ₹343.61 | ₹313.46 | ₹253.36 | ₹224.77 |
| Profit After Tax | ₹787.53 | ₹529.21 | ₹491.93 | ₹910.95 |
| EPS - Basic | ₹29.08 | ₹21.57 | ₹18.58 | ₹34.85 |
| EPS - Diluted | ₹29.08 | ₹21.57 | ₹18.58 | ₹34.85 |
Cash Flow · Consolidated
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Profit before tax | ₹1,131.14 | ₹842.67 | ₹745.29 | ₹1,135.72 |
| Income before WC changes | ₹1,859.03 | ₹1,332.54 | ₹980.47 | ₹1,330.83 |
| Change in Assets | -₹192.84 | -₹185.45 | ₹88.73 | -₹327.98 |
| Change in Liabilities | ₹16.38 | ₹93.86 | -₹39.74 | ₹55.23 |
| Change in WC | -₹176.46 | -₹91.59 | ₹48.99 | -₹272.75 |
| Cash flow from Operations | ₹1,321.32 | ₹944.65 | ₹805.81 | ₹856.04 |
| Cash flow from Investing | -₹869.50 | -₹1,291.79 | -₹725.00 | -₹855.05 |
| Cash flow from Financing | -₹282.98 | -₹552.55 | ₹507.24 | ₹426.81 |
| Total Cash Flow | ₹168.84 | -₹899.69 | ₹588.05 | ₹427.80 |
| Cash (Start of the year) | ₹755.79 | ₹1,578.98 | ₹990.93 | ₹559.01 |
| Cash (End of the year) | ₹924.63 | ₹755.79 | ₹1,578.98 | ₹990.93 |
Balance Sheet · Consolidated
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Non-Current Assets | ₹5,793.51 | ₹5,565.73 | ₹3,437.16 | ₹3,192.15 |
| Current Assets | ₹5,967.04 | ₹5,535.55 | ₹5,189.27 | ₹4,446.71 |
| Total Assets | ₹11,760.55 | ₹11,101.28 | ₹8,626.43 | ₹7,638.86 |
| Current Liabilities | ₹2,386.22 | ₹2,355.64 | ₹1,805.82 | ₹1,465.88 |
| Net Current Asset | ₹3,580.82 | ₹3,179.91 | ₹3,383.45 | ₹2,980.83 |
| Non-Current Liabilities | ₹986.06 | ₹1,018.64 | ₹905.29 | ₹604.09 |
| Equity Capital | ₹8,388.27 | ₹7,727.00 | ₹5,915.32 | ₹5,568.89 |
| Total Equity & Liabilities | ₹11,760.55 | ₹11,101.28 | ₹8,626.43 | ₹7,638.86 |
Income Statement · Standalone
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Revenue | ₹6,677.92 | ₹6,166.46 | ₹5,814.62 | ₹5,438.30 |
| Other Income | ₹71.29 | ₹111.29 | ₹111.19 | ₹52.92 |
| Total Revenue | ₹6,749.21 | ₹6,277.75 | ₹5,925.81 | ₹5,491.22 |
| Total Expenses | ₹5,467.90 | ₹5,322.23 | ₹5,175.32 | ₹4,417.11 |
| Profit Before Tax | ₹999.77 | ₹822.16 | ₹750.49 | ₹1,074.11 |
| Tax | ₹349.01 | ₹291.75 | ₹244.79 | ₹213.74 |
| Profit After Tax | ₹650.76 | ₹530.41 | ₹505.70 | ₹860.37 |
| EPS - Basic | ₹25.65 | ₹20.91 | ₹19.93 | ₹33.91 |
| EPS - Diluted | ₹25.65 | ₹20.91 | ₹19.93 | ₹33.91 |
Cash Flow · Standalone
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Profit before tax | ₹999.77 | ₹822.16 | ₹750.49 | ₹1,074.11 |
| Income before WC changes | ₹1,605.55 | ₹1,221.32 | ₹956.58 | ₹1,295.27 |
| Change in Assets | ₹43.76 | -₹160.96 | ₹70.75 | -₹304.48 |
| Change in Liabilities | ₹49.51 | ₹47.10 | -₹49.79 | ₹33.09 |
| Change in WC | ₹93.27 | -₹113.86 | ₹20.96 | -₹271.39 |
| Cash flow from Operations | ₹1,374.07 | ₹830.51 | ₹762.29 | ₹831.72 |
| Cash flow from Investing | -₹738.81 | -₹1,355.18 | -₹709.61 | -₹814.00 |
| Cash flow from Financing | -₹428.44 | -₹464.88 | ₹506.38 | ₹426.04 |
| Total Cash Flow | ₹206.82 | -₹989.55 | ₹559.06 | ₹443.76 |
| Cash (Start of the year) | ₹515.28 | ₹1,504.83 | ₹945.77 | ₹499.86 |
| Cash (End of the year) | ₹722.10 | ₹515.28 | ₹1,504.83 | ₹945.77 |
Balance Sheet · Standalone
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Non-Current Assets | ₹5,290.98 | ₹5,149.38 | ₹3,571.82 | ₹3,213.98 |
| Current Assets | ₹3,779.94 | ₹3,509.89 | ₹4,875.15 | ₹4,224.46 |
| Total Assets | ₹9,070.92 | ₹8,659.27 | ₹8,446.97 | ₹7,438.44 |
| Current Liabilities | ₹1,419.53 | ₹1,520.17 | ₹1,677.78 | ₹1,353.73 |
| Net Current Asset | ₹2,360.41 | ₹1,989.72 | ₹3,197.37 | ₹2,870.73 |
| Non-Current Liabilities | ₹759.77 | ₹790.39 | ₹891.89 | ₹608.95 |
| Equity Capital | ₹6,891.62 | ₹6,348.71 | ₹5,877.30 | ₹5,475.76 |
| Total Equity & Liabilities | ₹9,070.92 | ₹8,659.27 | ₹8,446.97 | ₹7,438.44 |
About IPCA Laboratories
Ipca Laboratories Limited is an India-based integrated pharmaceutical company. The Company is engaged in manufacturing and marketing over 350 formulations and approximately 80 active pharmaceutical ingredients (APIs) covering various therapeutic segments. It offers APIs, such as Atenolol, Chloroquine Phosphate, Chlorthalidone, Furosemide, Hydroxychloroquine sulfate, Losartan, Metoprolol Succinate, Metoprolol Tartrate, Pyrantel Salts and Propranolol. The Company offers brands, such as Zerodol, Lariago, HCQS, Perinorm, Rapither AB, Tenoric, Lumerax, Etova, Fexova, Malirid, Allsuth, Alwiz, AZR 50mg, Bacilon, Cinkona, Clarbact, Glyree MV, Halotop, Luliz, Ozepam, Pacimol, Pari, Xtor-F, Zabpro, Zilast, Ramcor, Sove, Venpower and Folitrax. The Company’s products are sold in over 100 countries across the globe. The Company has 18 manufacturing units in India manufacturing APIs and formulations. Its subsidiaries include Ipca Pharmaceuticals, Inc. and Ipca Pharma Nigeria Ltd.
IPCA Laboratories Financial Highlights
- Revenue: IPCA Laboratories reported revenue of ₹9,820.78 crore in FY26 vs ₹9,032.39 crore in FY25. It showed an increase of 8.73% on a yearly basis.
- Operating Profit: IPCA Laboratories reported an operating profit of ₹1,572.52 crore in FY26 vs ₹1,131.14 crore in FY25. It showed an increase of 39.02% on a year-on-year basis.
- Net Profit: IPCA Laboratories reported a net profit of ₹1,191.37 crore in FY26 vs ₹787.53 crore in FY25. It showed an increase of 51.28% on a yearly basis.
IPCA Laboratories Quarterly Result Highlights
- IPCA Laboratories reported revenue of ₹2,482.22 crore in Mar 2026, compared with ₹2,412.69 crore in Dec 2025, representing an increase of 2.88% on a quarter-on-quarter (QoQ) basis.
- IPCA Laboratories reported an operating profit of ₹404.45 crore in Mar 2026, compared with ₹445.98 crore in Dec 2025, representing a decrease of 9.31% on a quarter-on-quarter (QoQ) basis.
- IPCA Laboratories reported a profit of ₹309.40 crore in Mar 2026, compared with ₹364.05 crore in Dec 2025, reflecting a decrease of 15.01% on a QoQ basis.
- The earnings per share (EPS) of IPCA Laboratories stood at ₹29.08 during Mar 2026.
Similar Stocks
FAQs on IPCA Laboratories Share Price
What is IPCA Laboratories share price today?
IPCA Laboratories share price is ₹1,778.90 as on 03 Jul, 2026, 15:51 IST.
How has the IPCA Laboratories share price performed in the past?
In the last 1 year, IPCA Laboratories delivered a return of 25.66%. The IPCA Laboratories share price hit a high of ₹1,788.30 and low of ₹1,251.60.
How much is the Mutual Fund shareholding in IPCA Laboratories shares?
The Mutual Fund Shareholding in IPCA Laboratories was 31.24% at the end of Mar 2026.
What is the the 52-week high and low of IPCA Laboratories shares ?
The 52-week high and low of IPCA Laboratories share is ₹1,788.30 and ₹1,251.60 as of 03 Jul, 2026.
What is the market cap of IPCA Laboratories?
The market capitalisation of IPCA Laboratories is ₹43,596.50 Crores as on 03 Jul, 2026.
What are the stock symbols of IPCA Laboratories?
The stock symbol of IPCA Laboratories is IPCALAB on the NSE, 524494 on the BSE, and the ISIN is INE571A01038.
What was yesterday's closing price of IPCA Laboratories shares ?
IPCA Laboratories shares closed yesterday at ₹1,719.40 on NSE & ₹1,718.40 on BSE
How to buy IPCA Laboratories shares?
To buy IPCA Laboratories shares, open a demat account with Upstox and complete the KYC process. Once your account is set up, search for the stock and place your order.
Can I buy IPCA Laboratories shares on Holidays?
No, shares of IPCA Laboratories or any other publicly traded company cannot be bought or sold on holidays when the stock exchanges are closed. You can only buy or sell IPCA Laboratories shares on days when the stock exchanges are open for trading. It's important to check the NSE & BSE holidays calendar, before placing any trades to avoid any inconvenience.
What is the PE and PB ratio of IPCA Laboratories?
The PE and PB ratio of IPCA Laboratories is 36.83 and 5.41 respectively, as on 03 Jul, 2026, 15:51 IST.